Products

Our Products

At Lxbio Phar­ma­ceu­ti­cals, we are com­mit­ted to dis­cov­er bio­phar­ma­ceu­ti­cal solu­tions that aim to trans­form health­care and improve patient lives.

Our port­fo­lio encom­pass­es a range of inno­v­a­tive ther­a­pies devel­oped through advanced biotech­no­log­i­cal process­es.

Con­tact Us

TP-102

The Potential to Transform the Care of Diabetic Foot Infections

Pre­ci­sion against pathogens. Heal­ing beyond antibi­otics.

The Potential to Transform the Care of Diabetic Foot Infections

TP-102 is a Break­through Bac­te­rio­phage Ther­a­py for DIABETIC FOOT INFECTIONS.

TP-102 is the first top­i­cal bac­te­rio­phage cock­tail devel­oped specif­i­cal­ly to treat dia­bet­ic foot ulcers. Com­posed of five lyt­ic bac­te­rio­phages, TP-102 offers a tar­get­ed, micro­bio­me-spar­ing approach to erad­i­cate mul­tidrug-resis­tant pathogens, a grow­ing con­cern in the man­age­ment of chron­ic wounds.

TP-102 has demon­strat­ed safe­ty and effi­ca­cy in clin­i­cal tri­als, pro­mot­ing accel­er­at­ed heal­ing and bac­te­r­i­al clear­ance with no sys­temic adverse effects.

TP-102 has received FDA fast track and has com­plete phase 2b. This inno­v­a­tive plat­form has the poten­tial to rede­fine the stan­dard of care for dia­bet­ic foot infec­tions, offer­ing a next gen­er­a­tion solu­tion where tra­di­tion­al antibi­otics often fail.

Dis­cov­er more! (The con­tent on this web­site page con­tains images and visu­al mate­r­i­al that may be dis­turb­ing or upset­ting to some view­ers. By pro­ceed­ing, you acknowl­edge that you have been informed of the nature of the con­tent and accept full respon­si­bil­i­ty for your expe­ri­ence on this site.) 

LXOP01

The world’s first bacteriophage-based eye drop

Tar­get infec­tion. Pre­serve vision. Restore com­fort.

The world’s first bacteriophage-based eye drop

LXOP01 is a Bac­te­rio­phage Ther­a­py for BLEPHARITIS.

This inno­v­a­tive for­mu­la­tion har­ness­es the nat­ur­al antibac­te­r­i­al prop­er­ties of lyt­ic bac­te­rio­phages to selec­tive­ly tar­get and elim­i­nate drug resis­tant Staphy­lo­coc­cus and Pseudomonas species, a cause of Ble­phar­i­tis and chron­ic eye­lid inflam­ma­tion.

Unlike tra­di­tion­al anti­biotic, phages do not dis­rupt the healthy ocu­lar micro­bio­me and do not con­tribute to antibi­ot­ic resis­tance. Devel­oped using advanced sta­bi­liza­tion and deliv­ery tech­nolo­gies, the prod­uct ensures effec­tive pene­tration of biofilms and sus­tained antimi­cro­bial activ­i­ty.

Clin­i­cal­ly, it offers a nov­el, safe, and tar­get­ed approach that sig­nif­i­cant­ly reduces symp­toms, improves eye­lid health, and enhances both visu­al com­fort and patients’ qual­i­ty of life.

LXOP02

Anti-VEGF Lipid-based Nanoparticles in an Eyedrops Formulation

From Nee­dle to Drops. A Safer Future for Reti­nal Care.

Anti-VEGF Lipid-based Nanoparticles in an Eyedrops Formulation

LXOP02 is a Break­through on reti­na dis­ease for con­ve­nience and safe­ty for AMD & DME*.

Lxbio is devel­op­ing the first anti-VEGF eye drop for­mu­la­tion designed specif­i­cal­ly for the treat­ment of dia­bet­ic retinopa­thy.

This inno­v­a­tive solu­tion encap­su­lates the anti-VEGF agent with­in lipid-based nanopar­ti­cles, enabling effec­tive top­i­cal deliv­ery to the reti­na, a sig­nif­i­cant advance­ment over cur­rent inva­sive intrav­it­re­al injec­tion ther­a­pies.

By com­bin­ing nan­otech­nol­o­gy with a non-inva­sive admin­is­tra­tion route, this prod­uct aims to improve patient com­pli­ance, reduce treat­ment-asso­ci­at­ed risks, and expand access to care for mil­lions affect­ed by dia­bet­ic reti­nal di­seases.

AMD= Age-relat­ed mac­u­lar degen­er­a­tion ; DME= Dia­bet­ic mac­u­lar ede­ma.

LXDE01

Combining Corticosteroid with Targeted Bacteriophage Technology

Tar­get­ing inflam­ma­tion and infec­tion in one intel­li­gent treat­ment.

Combining Corticosteroid with Targeted Bacteriophage Technology.
LXDE01 Inno­v­a­tive top­i­cal com­bin­ing cal­cineurin inhibitor with bac­te­rio­phage for ATOPIC DERMATITIS

The prod­uct com­bines the  estab­lished clin­i­cal effi­ca­cy of cal­cineurin inhibitor with a tar­get­ed bac­te­rio­phage cock­tail specif­i­cal­ly direct­ed against Staphy­lo­coc­cus aureus, a key pathogen asso­ci­at­ed with dis­ease exac­er­ba­tion, skin bar­ri­er dis­rup­tion, and recur­rent flares in atopic der­mati­tis.

By simul­ta­ne­ous­ly reduc­ing cuta­neous inflam­ma­tion and selec­tive­ly mod­u­lat­ing path­o­gen­ic bac­te­r­i­al col­o­niza­tion with­out dis­rupt­ing the com­men­sal skin micro­bio­ta, LXDE01 aims to address both the immuno­log­i­cal and micro­bi­o­log­i­cal dri­vers of dis­ease. This dual-mech­a­nism approach is expect­ed to enhance ther­a­peu­tic effi­ca­cy, improve treat­ment con­ve­nience, and poten­tial­ly reduce recur­rence rates com­pared with con­ven­tion­al top­i­cal ther­a­pies.

LXON01

A phage-powered Precision Platform for Drug Delivery

Smarter tar­get­ing.

image6

LXON01 Phage-based Deliv­ery Sys­tems

Based on a mod­u­lar archi­tec­ture built on a Fil­a­men­tous bac­te­rio­phage, a next-gen­er­a­tion tar­get­ed can­cer ther­a­py built using an engi­neered M13 bac­te­rio­phage. This nanoscale plat­form acts as a pro­gram­ma­ble bio­log­i­cal car­ri­er capa­ble of deliv­er­ing tar­get­ing mol­e­cules, cyto­tox­ic drugs, and immune-stim­u­lat­ing sig­nals simul­ta­ne­ous­ly with­in a sin­gle ther­a­peu­tic sys­tem.

Pipeline Clínico
Prod­uctIndi­ca­tionProd­uctProof
of con­cept		Pre­clin­i­cal
devel­op­ment		Clin­i­cal tri­als
Phase 1		Clin­i­cal tri­als
Phase 2		Clin­i­cal tri­als
Phase 3
Top­i­cal Bac­te­rio­phages
cock­tail Dia­betes		Dia­bet­ic foot
infec­tion		TP-102
COMPLETED
IN
DEVELOPMENT
Anti-VEGF encap­su­lat­ed in
nanopar­ti­cles eye­drops		Mac­u­lar Degen­er­a­tion
& Dia­bet­ic retinopa­thy		LXOP02
Eye­drops gel
Bac­te­rio­phages		Ble­phar­i­tis & Ocu­lar infec­tionLXOP01
Phage-based
Deliv­ery Sys­tems		Sev­er­al ther­a­peu­ti­cal
tar­gets		LXON01
Top­i­cal Bac­te­rio­phages
plus cal­cineurin inhibitor		Atopic
Der­mati­tis		LXDE01